Imaging in therapeutic trials is the key process in expanding the understanding, methodology and metrics which are required to make determinations in drug targeting and efficacy.
This spans most all imaging modalities, organ systems, and therapeutic areas.
BioMolecular Imaging has extensive, decades-long experience in anatomic and molecular imaging as applied to the conduct of therapeutic trials and the determination of drug targeting and efficacy. This spans most all imaging modalities, organ systems, and therapeutic areas.
EARLY PHASE
Early phase imaging often examines the behavior of a new molecular agent that is a counterpart to a therapeutic drug and binds to the same target site.
LATE PHASE
Late phase trials often combine a therapeutic target imaging agent with the therapeutic drug as an approach to improve patient outcomes. This powerful strategy can be extended to a commercializable imaging-therapeutic combination to stratify patients for treatment and/or to monitor patient response.
About BioMolecular Imaging
BioMolecular Imaging (BMI Consultants) is a molecular imaging and clinical trial consultancy owned and operated by Dr. J. James Frost M.D./Ph.D out of Baltimore Maryland. BMI has been involved with clinical, therapeutic & diagnostic imaging focused on Oncology, Brain, Biomarkers, Cardiology and Central Image Interpretations for over 20 years.
To learn more about BioMolecular Imaging, please visit https://www.BioMolecularImaging.com or connect with:
SoundCloud - https://soundcloud.com/BioMolecular-Imaging
Facebook - https://www.facebook.com/BMIConsultants
Twitter - https://twitter.com/BMIConsultants
Copyright © 2022 BioMolecular Imaging
BioMolecular Imaging is a registered trademark of BioMolecular Imaging D.B.A. BMI Consultants
Comentarios